Lilly and Resilience Commit $750M to Boost U.S. Drug Manufacturing
LLY sits 90% above its 52-week low of $623.78.
Summary
Eli Lilly and Resilience are investing $750 million to expand U.S. manufacturing capacity, creating 400 high-skilled jobs in Ohio. This directly addresses supply constraints for Lilly's fast-growing obesity and diabetes portfolio, including Zepbound and Foundayo. The move follows a series of positive clinical and market-access developments for those drugs, reinforcing Lilly's commitment to meeting surging demand. The investment signals confidence in long-term volume growth and may ease investor concerns about production bottlenecks.
Updates
· Wiseek News — The expansion will add KwikPen production and site preparation begins now, with full operations expected by early 2027.
At the time of this announcement, LLY was trading at $1,187.81 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,249.45. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.